New drug cocktail takes on tough lymphoma
NCT ID NCT07197307
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 28 times
Summary
This study tests a combination of two drugs, loncastuximab tesirine and epcoritamab, in people with aggressive B-cell lymphoma that has returned or not responded to treatment. About 120 adults who have not had CAR-T therapy or whose CAR-T therapy failed will receive the drug combo. The goal is to see if the combination can shrink or eliminate tumors and how long that effect lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitätsklinikum Münster, Medizinische Klinik A
Münster, 48149, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.